EGFR and non-small cell lung carcinoma: Gefitinib (Iressa), an orally potent and selective ATP-competitive inhibitor of EGFR tyrosine kinase, is commonly used to treat locally advanced or metastatic NSCLC with sensitive EGFR mutations [6].